Trial of Yellow Fever Inactivated Vaccine

Inclusion Criteria:

- All aspects of the protocol explained and written informed consent obtained from the
subject;

- Aged 18 to 49 years, inclusive;

- In good general health, without significant medical history, physical examination
findings, or abnormal laboratory results; and

- Subject must be available for the study duration, including all planned follow-up
visits.

- For female subjects of child bearing potential: Negative serum pregnancy tests at Day
-7 to -1, and negative urine pregnancy tests prior to vaccination on Days 0, in
conjunction with a menstrual and contraceptive history indicating a low probability
of pregnancy in the opinion of the physician. Females of childbearing potential will
be required to be correctly using an efficacious hormonal method of contraception or
intrauterine device for at least 1 month before randomization and during the on-study
phase to Day 42. Barrier methods of contraception will not be considered acceptable
for study entry. Female subjects of child-bearing potential will acknowledge by
signing their informed consent that contraception will be correctly practised during
the specified periods and will specify the method used. Female subjects unable to
become pregnant must have this documented (e.g. tubal ligation, hysterectomy or
postmenopausal [at least one year since last menstrual period]).

Exclusion Criteria:

- History of travel to South America or SubSaharan Africa;

- History of active duty military service;

- History of vaccination against yellow fever, tick-borne encephalitis (TBE), or
Japanese encephalitis;

- Went to primary (grade) school in Austria, Germany, Japan, South Korea, India,
Thailand, Nepal, Vietnam, or Taiwan (where TBE vaccination is practiced)

- History of dengue fever;

- Known or suspected immunodeficiency disorder, including leukemia, lymphoma,
generalized malignancy, or treatment with immunosuppressive medications, including
corticosteroids, alkylating agents, antimetabolites, or radiation therapy. Low dose
steroids (≤ 10 mg prednisone or equivalent, topical or
intra-articular/bursal/tendon/epidural injections of corticosteroids) do not
constitute a reason for exclusion;

- History of an autoimmune disorder, including systemic lupus, rheumatoid arthritis,
scleroderma, other collagen vascular disease, multiple sclerosis, etc. Psoriasis
limited to cutaneous manifestations is not an exclusion criterion;

- Prior history of anaphylaxis to foods, hymenoptera stings, vaccines or drugs;

- Transfusion of blood or treatment with any blood product, including intramuscular or
intravenous serum globulin within 3 months of the Screening Visit or anticipated up
to Study Day 42;

- Administration of another vaccine within 30 days preceding the screening visit or
anticipated up to Day 42 (these subjects may be rescheduled for vaccination at a
later date);

- Participation in another clinical trial within 60 days of the screening visit;

- Positive serum or urine pregnancy test prior to vaccination (women of child-bearing
potential or lactation or intended pregnancy during study period);

- Abnormalities on laboratory assessment (i.e. meeting the criteria defined for a mild,
moderate or severe adverse event in Appendix 1, a1A);

- Seropositive to HIV or HCV or positive for HBsAg;

- Physical examination indicating any clinically significant medical condition;

- Body temperature >38.1°C (100.6°F) or acute illness within 3 days prior to
vaccination (subject may be rescheduled);

- Intention to travel out of the area prior to the study visit on Day 42;

- History of excessive alcohol consumption, drug abuse, significant psychiatric
illness; and

- Intention to increase normal exercise routine, participate in contact sports or
strenuous weight lifting or to initiate vigorous exercise from Screening until after
Day 42.